Building on previously presented work, researchers at M.D. Anderson Cancer Center in Houston have published new findings that show that evaluating the change of CA-125 over time shows promise as a screening tool for early-stage ovarian cancer. OCRF grantees Karen Lu, MD and Robert Bast, MD were first and senior author on the paper, which … Continued
In a review article published online in Oncogene on August 12, OCRF-funded researchers provide a comprehensive review of pre-clinical models used in ovarian cancer research. The authors, including OCRF grantees Ernst Lengyel, Daniela Matei, Ken Nephew, and Joanna Burdette, explore current experimental models and reflect on the strengths and weaknesses for each method. In addition, … Continued
Two dogs at the University of Pennsylvania’s Penn Vet Working Dog Center are learning how to smell tissue that is in early stages of ovarian cancer. The dogs have been able to smell the cancerous tissue 100% of the time. The dogs are part of an interdisciplinary research project to help scientists discover a chemical … Continued
Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer. Data from 191 patients with stage III or IV ovarian cancer who underwent surgery followed by platinum-based chemotherapy were analysed. The results, which were published in Gynecologic Oncology on … Continued
Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network. He discussed the heterogeneity of ovarian cancer, angiogenesis inhibitors and new drugs in the pipeline. The full interview can be found here
Research published online last week in Nature Communications suggests that some of the cell lines most frequently used to study high-grade serous ovarian cancer (HGSOC) may not be the best. OCRF grantee and SAC member Douglas Levine, MD was one of the authors of the paper. Cell lines derived from tumor tissue are the most … Continued
In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated with survival in various subtypes of ovarian cancer. To date, few biomarkers of ovarian cancer prognosis have been established. The study, which included 2,933 women, … Continued
Women with a family history of breast cancer but no BRCA1/2 mutation were found to be at average risk for developing ovarian cancer. The prospective study of 8005 women from a breast cancer family history clinic found that women with a BRCA2 mutation had a 17-times higher risk of developing ovarian cancer than average, and … Continued
In an interview, 3-time grantee Dr. Zhang discusses his research and what it means to receive an award from OCRF.
We recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO), an annual event that gathers thousands of cancer researchers from around the world. Many new studies on or related to ovarian cancer were presented at this year’s ASCO meeting. Click here to read a summary of ovarian cancer research from … Continued
In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et al. v. Myriad Genetics, the court considered the validity of patents held by the Utah-based company Myriad Genetics for the BRCA1 and BRCA2 genes, which … Continued
Society for Nuclear Medicine and Molecular Imaging (SNMMI) Advocate Report from Laurel Pracht As a member of the SNMMI Advocate Advisory Board, formed in 2010 to better bridge the gap between the patient and nuclear medicine communities, I represent the ovarian patient community. Other diseases, including cancer, brain and heart disease are represented as well. … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
